NCT04503174View on ClinicalTrials.gov

Control-IQ Observational (CLIO) Post-Approval Study

CompletedOBSERVATIONAL
Enrollment

3,157

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

June 2, 2023

Study Completion Date

June 26, 2023

Conditions
Diabetes Mellitus, Type 1
Interventions
DEVICE

t:slim X2 pump with Control-IQ technology

Real-world use

Trial Locations (1)

92121

Tandem Diabetes, San Diego

All Listed Sponsors
collaborator

University of California, San Diego

OTHER

lead

Tandem Diabetes Care, Inc.

INDUSTRY

NCT04503174 - Control-IQ Observational (CLIO) Post-Approval Study | Biotech Hunter | Biotech Hunter